Contact:
4008465777
-
About Us
News & Events
-
11-01
Tonghua Dongbao: Net profit excluding non-recurring gains and losses attributable to shareholders of the parent company up 26.19% YoY in Q3 2023
On the evening of October 30, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") released its quarterly report for Q3 2023. In Q3 2023, the Company's revenue was R...
-
10-24
Tonghua Dongbao: BC Combo meets primary endpoint in phase I clinical trial in Germany
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") completed three key phase I clinical trials of BC Combo (THDB0207), a soluble insulin glargine and insulin lispr...
-
10-17
Tonghua Dongbao obtains the Pharmaceutical Product Registration Certificate for empagliflozin tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate for empagliflozin tablets issued by the Nationa...
-
09-19
Tonghua Dongbao teams up with Kingfriend to enter US insulin market
On September 17, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") and Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd. ("Kingfriend") announced a strategic partners...
-
09-05
Tonghua Dongbao announces NMPA acceptance of its NDA application for Etoricoxib Tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") received the notice of acceptance (No. CYHS2302352, CYHS2302353, and CYHS2302354) from the National Medical Prod...
-
08-22
Tonghua Dongbao announces NMPA acceptance of its clinical trial application for oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules)
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...